(PDF) Reversion and Non-Reversion Mechanisms of Resistance

Reversion and Non-Reversion Mechanisms of Resistance to PARP Inhibitor or Platinum Chemotherapy in BRCA1/2-mutant Metastatic Breast Cancer

doi 10.1101/832717

Full Text

Abstract

Available in full text

Date

November 10, 2019

Authors

Adrienne G. Waks

Bose Kochupurakkal

Jorge Buendia Buendia

Maxwell R. Lloyd

Melissa E. Hughes

Samuel S. Freeman

Patricia LoRusso

Viktor A. Adalsteinsson

Sara M. Tolaney

Ursula Matulonis

Alan D. D’Andrea

Geoffrey I. Shapiro

Publisher

Cold Spring Harbor Laboratory

Related search

RING Domain–deficient BRCA1 Promotes PARP Inhibitor and Platinum Resistance

Journal of Clinical Investigation

English

The PARP Inhibitor AZD2281 (Olaparib) Induces Autophagy/Mitophagy in BRCA1 and BRCA2 Mutant Breast Cancer Cells

International Journal of Oncology

Cancer Research

English

PARP Inhibitor Treatment in Ovarian and Breast Cancer

Current Problems in Cancer

Cancer Research

English

Lurbinectedin Is Active in Patients With BRCA1/2 Mutant Breast Cancer

Cancer Discovery

English

Metronomic Chemotherapy in Metastatic Breast Cancer

Novel Research in Sciences

English

Combination Chemotherapy in Metastatic Breast Cancer

English

Combination Chemotherapy in Metastatic Breast Cancer

English

Alexithymia Reversion in Psoriasis

British Journal of Dermatology

English

PARP Inhibitors in Ovarian Cancer: Sensitivity Prediction and Resistance Mechanisms

Journal of Cellular and Molecular Medicine

Molecular Medicine

English